Navigation Links
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models
Date:7/2/2009

EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), National Institutes of Health and Lixte reported that its novel compound, LB-1.2, enhances the effectiveness of two standard chemotherapy drugs in mouse models of human cancers. This research is being conducted under a Cooperative Research and Development Agreement between NINDS and Lixte. The report was published online in the early edition (June 29) of the Proceedings of the National Academy of Science (US). The print version will appear July 14.

Dr. John S. Kovach, President and CEO of Lixte, said "LB-1.2 exerts anti-cancer activity directly on the cancer cell and, more dramatically, by preventing cancer cells from recovering from DNA-damage produced by standard anti-cancer drugs. In mouse models, LB-1.2 plus Temozolomide caused complete regression without recurrence in 50 % of animals bearing tumors of human glioblastoma multiforme (GBM), the most common and aggressive brain tumor of adults, and also, marked regression of neuroblastoma, the most common cancer of children. Temozolomide, the standard drug for the treatment of patients with GBM, by itself caused regression but with recurrence of all tumors."

Dr. Kovach added "that, since LB-1.2 has a biochemical action similar to an older drug used for anticancer treatment for many years in China, we are cautiously optimistic that LB-1.2 will be well tolerated by cancer patients and hopefully, will potentially be as effective as it is in animal models of human cancer. We believe that adding LB-1.2 may be a general method for improving the effectiveness of several standard anticancer drugs not only against tumors of the brain and neural tissue but also against other cancers sensitive to drugs that work by damaging DNA. Safe
'/>"/>

SOURCE Lixte Biotechnology Holdings
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
2. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
3. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
4. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
5. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
6. Johnson & Johnson Announces Regulatory Clearance for Its Planned Acquisition of Cougar Biotechnology
7. A-WIT Technologies Releases World's First Low Cost C Stamp(TM) Based Biotechnology Laboratory in a Box
8. Yongye Biotechnology International Receives License to Manufacture Products
9. Johnson & Johnson Begins Tender Offer to Acquire Cougar Biotechnology
10. Microfluidics Expands Distributorship in Japan with Exclusive POWREX Partnership to Meet Increased Demand in Pharmaceutical, Biotechnology and Energy Industries
11. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015  AACC, a ... better health through laboratory medicine, is pleased to ... Clinical Chemistry , has increased to 7.9 ... This increase places Clinical Chemistry in ... reflects the significant influence of the research it ...
(Date:6/29/2015)... Calif. , June 29, 2015   Veracyte, ... company pioneering the field of molecular cytology, today announced ... News Group,s prestigious Top Workplaces list for the second ... Workplace winners based solely on an annual survey of ... and honored that the degree to which Veracyte values ...
(Date:6/26/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... listed in the management information circular dated June 1, ... Meeting of Shareholders, held earlier today, June 26 ... 5 nominees proposed by management were elected as ... Company,s next Annual Meeting of Shareholders or until ...
(Date:6/26/2015)... 23, 2015 Research ... of the "Global Cancer Biosimilars Market Opportunity ... Market introduction of cancer biosimilar is required because ... Chemotherapeutic drugs have dominated the cancer segment for ... introduced in past few years. They are biologic ...
Breaking Biology Technology:AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 3iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3Global Cancer Biosimilars Market Opportunity Outlook 2Global Cancer Biosimilars Market Opportunity Outlook 3
... initiatives, open model of information sharing, ... ... The Duke University Health,System has licensed Velos eResearch to ... Velos, Inc. will,play a key role in these clinical trials ...
... Initiate Process to Re-list Common Shares, SOUTH ... Sheets: VXGN) announced today that it has filed ... 2007, thereby bringing the company current,on its financial ... (SEC). (Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO ) Accordingly, ...
... (Nasdaq: MLNM ) today announced the election ... of Directors. Dr. Leiden, a,Managing Director at Clarus ... distinguished career of more than 20 years of ... joining Clarus, Dr. Leiden,served as President and Chief ...
Cached Biology Technology:Velos eResearch System License Agreement Announced 2Velos eResearch System License Agreement Announced 3Velos eResearch System License Agreement Announced 4Velos eResearch System License Agreement Announced 5VaxGen Files Last Outstanding Periodic Report With SEC 2Life Sciences Leader Joins Millennium Board of Directors 2Life Sciences Leader Joins Millennium Board of Directors 3
(Date:6/17/2015)... Deutschland und GERMANTOWN, Maryland , June ... ®   Produktlinie mit DNA-Tests verbessert den ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) hat ... STR-Testkits der Produktlinie Investigator ® ... Markt eingeführt. Die neuen Kits zur Erstellung genetischer Fingerabdrücke ...
(Date:6/16/2015)... 16, 2015  With the increasing number and severity ... top concern. The recent compromise of Federal employee ... strong authentication within government agencies. HYPR Corp. ... password (OTP) authenticator, has been submitted for testing and ... 3 validation for tamper proofing. The ...
(Date:6/15/2015)... Conn. , Jun. 15, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces that ... be showcased to media at Digital Experience! @ NYC June ... summer showcase of the latest innovation in technology to over ... will be held at the Metropolitan Pavilion in ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
... (FASD) and Fetal alcohol syndrome (FAS) cause malformations ... mental and behavioral abnormalities. The African frog, Xenopus, ... development since these embryos are large, easy to ... New research uses this system to address ...
... "Digital Fingerprinting for Kids" event on April 18 at ... Beach CHESAPEAKE, Va., April 2 Turner Network ... Broadcasting System, Inc. (TBS, Inc.), and truTV, are partnering with ... highly-regarded "Digital Fingerprinting for Kids" event , a service ...
... By identifying a novel compound that primes a plant,s immune ... of Chicago may be on a path to developing disease-resistant ... a team that includes Tim Tschaplinski of the Department of ... priming the immunity response in Arabidopsis, a small flowering plant ...
Cached Biology News:Frogs reveal clues about the effects of alcohol during development 2truTV and Cox Offer Free Digital Fingerprinting to Help Prevent Crimes Against Children 2truTV and Cox Offer Free Digital Fingerprinting to Help Prevent Crimes Against Children 3Researchers discover primer to plant defense system 2
HybriWell seals securely to a microscope slide surface in seconds to enclose single or multiple specimens in a small reagent volume and eliminate evaporation....
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
... Human IgM Assay Kit to address the ... assay for Human IgM that eliminates the ... a simple mix-and-read assay that allows the ... ng/ml in approximately 30 minutes. The Pierce ...
AC input: 230 V...
Biology Products: